PV Core Vocabulary — AE, ADR, SAE, SUSAR & the Valid ICSR

An Adverse Event is any untoward medical occurrence in a patient given a medicinal product, which does not necessarily have a causal relationship with the treatment. A patient on blood pressure medication who slips and breaks their wrist in the bathroom has experienced an AE — the drug almost certainly didn’t cause it, but it happened while they were on the drug, so it’s documented. An Adverse Drug Reaction is a response to a medicinal product that is noxious and unintended — it implies at least a reasonable possibility of causation. A patient who develops a dry, persistent cough two weeks after starting an ACE inhibitor has an ADR — that cough is a well-known effect of the drug class.

"Serious" is not the same as "severe" — severity is about intensity, seriousness is a specific regulatory classification based on six defined criteria, and an event only needs to meet one to qualify as an SAE: death; life-threatening (immediate risk of death at the time of the event); hospitalisation (initial or prolonged); persistent or significant disability/incapacity; a congenital anomaly or birth defect in offspring of an exposed patient; or "other medically important condition" — a catch-all that lets medical judgment classify a genuinely serious situation that doesn’t fit the other five, such as a severe allergic reaction requiring emergency outpatient treatment with no hospitalisation.

SUSAR — Suspected Unexpected Serious Adverse Reaction — sits at the intersection of three concepts that must ALL be true simultaneously: suspected (the reporter suspects the drug caused it), unexpected (not listed in the Investigator Brochure for trials, or the approved label/Reference Safety Information for marketed drugs), and serious (meets one of the six SAE criteria). Miss any one of the three, and it is not a SUSAR — only the full combination triggers the industry’s fastest reporting timelines.

An ICSR (Individual Case Safety Report) is the standardised document used to report a single adverse event case anywhere in the world, transmitted electronically in E2B(R3) XML format. A valid ICSR requires four minimum elements — an identifiable patient, an identifiable reporter, a suspect drug, and an adverse event — universal across FDA, EMA, CDSCO, and PMDA. And Day-0, the single most important date in pharmacovigilance, is the day the company first becomes aware of the case — not when the event itself happened. A serious reaction that occurred three months ago but was only reported to the company today has a Day-0 of today; the regulatory clock starts from company awareness, not event date.

Try applying all of this to a single scenario: a patient calls a company’s medical information line and mentions, almost in passing, that they were hospitalised last month after starting a new medication. That one sentence contains a full triage decision. Is it a valid ICSR? Check the four elements — you have a patient, a reporter (the caller), a drug, and an event, so yes. Is it serious? Hospitalisation is one of the six SAE criteria, so yes. Could it be a SUSAR? That depends on whether it’s unexpected — you’d need to check the product label or Investigator Brochure. And Day-0 is today, the day the company learned about it — not the date of the hospitalisation itself. This exact chain of judgment happens dozens of times a day in any PV department.